The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Bariatric surgery is a major operative procedure that caries significant morbidity and mortality risks due to the comorbid diseases seen in this patient population.
This procedure is increasing in frequency as more patients are willing to have it and more surgeons are becoming proficient.
The...
TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin. Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel).
The benefit came at a cost of increased serious bleeding (1.4%, vs....
The announcement the new trial comparing Lipitor to Crestor is interesting but not unexpected. It is timed to end near the end of lipitor's patent. A win- which is likely- will certainly help AZN sell their drug against the much cheaper generic lipitor.
Lipitor is the dominant statin on the market and has an indication for reducing the risk of heart attack and stroke. Crestor is more potent than Lipitor, but, because it was approved later, has less data to show for and no indication for lowering the risk of clinical events. Moreover, Zocor (Simvastatin)...
Impressive data on Ranexa in HGBA1c. The result of a decrease of 0.64 vs baseline and 0.43 vs placebo are at first glance underwhelming. But a closer looks shows that the results are realy quite impressive
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal...
Apparently doctors aren't quite as easily manipulated by pharma as we all thought. Despite a vigorous marketing effort, Bidil was seen by cardiologist as what it is- an expensive combination of two generics and was not used- even after insurance companies started to pay for it.
The reality that the actual details of the ENHANCE have not been circulated and that alternate explanations or caveats may be raised is probably unimportant. The bottom line carries the day and the bottom line is that the trial's title, ENHANCE, was not achieved by the addition of VYTORIN when...